Newsletter of MEDICA | View in browser | Deutsch | Print
Header of MEDICA Newsletter

Predicting the most effective treatment for IBD

Dear Sir or Madam,

The earlier treatment is started, the better. But treatment does not always work equally well for all patients despite having the same disease. In the case of inflammatory bowel disease, the results of therapy can differ from person to person as well. A research project led by a young physician from Kiel has therefore set itself the goal of being able to predict in the future which biologics therapy will deliver the best possible results for each individual. You can find out how this is to be achieved in our interview.

Enjoy reading!

Anne Hofmann
Editorial team MEDICA-tradefair.com

Table of Contents

Topic of the Month: Helper and game changer
Interview: Predicting the most effective treatment for IBD
Newsletter Service
RSS Service
Newsletter Archive
Image: Banner with the text: MEDICA DEEP DIVE, We. talk. Healthcare; Copyright: Messe Düsseldorf

Molecular markers: predicting the most effective treatment for IBD

Interview

Image: Person in the laboratory holding cell samples under the microscope; Copyright: MICROGEN@GMAIL.COM
Inflammatory bowel disease (IBD) is a group of disorders that cause chronic inflammation in the intestine. Early effective treatment can help manage this condition and improve the quality of life of patients. A research project aims to identify molecular markers to better assess the chances of success of certain biological therapies and subsequently determine the best individualized treatment plan.
Click here for the interview
Molecular markers: predicting the most effective treatment for IBD
All interviews at MEDICA-tradefair.com
To top

Big Data: Helper and game changer in laboratory medicine and genetics

Topic of the Month

Image: Gloved hand holds a cell culturing vessel in front of a screen with the depiction of a genetic analysis; Copyright: westend61
Big data, the use of large volumes of data in diagnostics and research, is giving medical science a powerful boost. Especially in laboratory medicine, big data can provide unprecedented support as doctors must consider a multitude of data and parameters to facilitate accurate medical decision-making.
Read more about our Topic of the Month
Helper in laboratory medicine and genetics
Big Data in genetics: reaching diagnosis through heaps of data
To top

Laboratory equipment and diagnostic tests, Company News

GeneProof merges with American Laboratory Products Company

GeneProof a.s.

BRNO, Czech Republic and SALEM, NH, USA – April 21, 2022: GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic, today announced a merger with American...
read more
To top

Newsletter Service

You like our newsletter? Then please recommend us: Forward this newsletter or the link www.MEDICA.de/news_login_2 to your friends and colleagues.

If you have difficulties with your order, please write an e-mail to redaktion@medica.de.

To top
Legal disclaimer

Messe Düsseldorf GmbH
Messeplatz, Stockumer Kirchstr. 61
40474 Düsseldorf, Germany

Phone: +49 211 4560-01
Fax: +49 211 4560-668
www.messe-duesseldorf.de
info@messe-duesseldorf.de

County Court Düsseldorf HRB 63

Board of Managing Directors: Wolfram N. Diener (Chairman), Bernhard J. Stempfle, Erhard Wienkamp

Chairman of Supervisory Board: Mayor Dr. Stephan Keller

Messe Düsseldorf GmbH processes personal data relating to you. You can find more information - also on your rights - in the privacy policy of Messe Düsseldorf GmbH available at www.messe-duesseldorf.de/privacy. In principle, i.e. subject to legal restrictions, you may at any time object to the processing of your personal data either on the aforementioned website, via e-mail to privacy@messe-duesseldorf.de or via postal mail to Messe Düsseldorf GmbH, G2-RV, PF 101006, 40001 Düsseldorf, Germany.

Facebook Twitter LinkedIn YouTube

Should you no longer wish to receive our newsletter, please click here.